PCK Stock Overview
Develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PainChek Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.025 |
| 52 Week High | AU$0.044 |
| 52 Week Low | AU$0.024 |
| Beta | 0.76 |
| 1 Month Change | -10.71% |
| 3 Month Change | -16.67% |
| 1 Year Change | -28.57% |
| 3 Year Change | -53.70% |
| 5 Year Change | -86.84% |
| Change since IPO | -57.63% |
Recent News & Updates
Recent updates
We're Keeping An Eye On PainChek's (ASX:PCK) Cash Burn Rate
Jul 04
Is PainChek (ASX:PCK) In A Good Position To Invest In Growth?
Feb 08Will PainChek (ASX:PCK) Spend Its Cash Wisely?
Jul 05Companies Like PainChek (ASX:PCK) Can Afford To Invest In Growth
Jan 26We're Interested To See How PainChek (ASX:PCK) Uses Its Cash Hoard To Grow
Sep 07When Can We Expect A Profit From PainChek Limited (ASX:PCK)?
May 07PainChek (ASX:PCK) Is In A Strong Position To Grow Its Business
Mar 01Market Sentiment Around Loss-Making PainChek Limited (ASX:PCK)
Nov 20Shareholder Returns
| PCK | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | -7.4% | 1.7% | -0.5% |
| 1Y | -28.6% | 136.9% | 8.2% |
Return vs Industry: PCK underperformed the Australian Healthcare Services industry which returned 136.9% over the past year.
Return vs Market: PCK underperformed the Australian Market which returned 8.2% over the past year.
Price Volatility
| PCK volatility | |
|---|---|
| PCK Average Weekly Movement | 10.9% |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: PCK has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PCK's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Philip Daffas | www.painchek.com |
PainChek Limited develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. The company offers PainChek, which uses cameras in smartphones and tablets for a facial scan that is analyzed in real time using facial recognition software to indicate the presence of pain. It serves patients suffering with dementia and pre-verbal infants; and the aged care, disability, home care, hospital, and infant sectors.
PainChek Limited Fundamentals Summary
| PCK fundamental statistics | |
|---|---|
| Market cap | AU$40.93m |
| Earnings (TTM) | -AU$8.31m |
| Revenue (TTM) | AU$2.67m |
15.3x
P/S Ratio-4.9x
P/E RatioIs PCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCK income statement (TTM) | |
|---|---|
| Revenue | AU$2.67m |
| Cost of Revenue | AU$1.95m |
| Gross Profit | AU$726.66k |
| Other Expenses | AU$9.03m |
| Earnings | -AU$8.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0051 |
| Gross Margin | 27.20% |
| Net Profit Margin | -310.93% |
| Debt/Equity Ratio | 0% |
How did PCK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 09:21 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PainChek Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martyn Jacobs | Canaccord Genuity |
| Ian Martin | New Street Research LLP |